The Under the Radar report suggests a profit of $4b for Retts and Fragile X during the orphan drug exclusivity period (7 years in the US, 10 years in Europe). Bell Potter estimates peak global sales of approx. US$3b per annum for Rett and Fragile X.
Ann: Annual Report to shareholders-NEU.AX, page-41
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.94 |
Change
-0.020(0.15%) |
Mkt cap ! $1.609B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.70 | $2.494M | 193.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 262 | $12.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.94 | 485 | 19 |
View Market Depth
| Last trade - 13.40pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |